A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
Rituximab
Medicine
Pharmacological class:
Marketed formulations:
Active moieties:
Active ingredient of formulation:
Active moiety of formulation:
Active moiety of drug:
Facts from the Community
From the BioVenturist base
Sales:
| Amount | Year | Area | Company Reporting |
|---|---|---|---|
|
|
||
|
|
||
|
|
Brand Names:
- Rituxan
- MabThera